Grant of Awards

About this update from Oxford Biomedica Plc

  OXB Grant of Awards   Oxford, UK - 08 April 2026 :  OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, announces that on 07 April 2026, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Company's 2024 Long Term Incentive Plan ("LTIP"), including R estric ted S hare U nits ("RSU") and the Company's 2024 Deferred Bonus Plan ("DBP"). As detailed in the recently published 2025 Directors' Remuneration Report:- Re-instated LTIP awards: the LTIP grants in respect of 2024 and 2025, detailed below, reinstate the originally intended grant level for Dr. Frank Mathias and Dr. Lucinda Crabtree's 2024 and 2025 LTIP awards. The 2024 and 2025 LTIP awards were scaled back, primarily to manage the headroom available under the OXB share plans. The re-instatement honors the terms on which Dr. Mathias and Dr. Crabtree were recruited and reflects the Comp any's performance detailed in the 2025 Annual report and accounts . The re-instated LTIP awards remain subject to the original performance conditions and post-vesting holding periods, ensuring that the vesting of the awards is subject to the sustained stron g performance of the business. LTIP - Grant in respect of 2026: The 2026 LTIP metrics are 60% revenue, 40% Operating EBITDA margin, with target ranges in each case assessed on a constant currency basis which is set out in the Company's Directors' Remuneration Report for 2025.   Type Name of individual Title Number of share options granted LTIP - Grant in respect of 2026 Dr. Frank Mathias Chief Executive Officer 478,119 LTIP - Grant in respect of 2025 46,195 LTIP - Grant in respect of 2024 43,790 2026 DBP Dr. Frank Mathias Chief Executive Officer 71,891 LTIP - Grant in respect of 2026     Dr. Lucinda Crabtree     Chief Financial Officer   156,884 LTIP - Grant in respect of 2025   26,526 LTIP - Grant in respect of 2024   12,876 2026 DBP Dr. Lucinda Crabtree Chief Financial Officer 47,179 LTIP - Grant in respect of 2026 Natalie Walter Chief Legal Officer and Group Company Secretary 75,479 2026 DBP Natalie Walter Chief Legal Officer and Group Company Secretary 12,459 LTIP - Grant in respect of 2026 Dr. Kyriacos Mitrophanous Chief Innovation Officer 72,391 2026 DBP Dr. Kyriacos Mitrophanous Chief Innovation Officer 10,841 LTIP - Grant in respect of 2026 Lisa Doman Chief People Officer 69,992 2026 DBP Lisa Doman Chief People Officer 10,629 LTIP - Grant in respect of 2026   Dr. Sébastien Ribault   Chief Business Officer   107,10 2 2026 DBP Dr. Sébastien Ribault Chief Business Officer 14,908 LTIP - Grant in respect of 2026   Mark Caswell   Site Head, UK Operations   49,431 2026 LTIP RSU Dr. Sabine Sydow Chief of Staff 7,036 2026 LTIP RSU Dr. Melanie Kearney Global Head of Quality 12,711 2026 LTIP RSU John Foy Site Head, Durham O perations 12,380 2026 LTIP RSU Stéphanie Colloud Site Head and General Manager of France Operations 10,357 2026 LTIP RSU Kathleen Miller Head of Human Resources ( and acting Interim Site Head, Bedford) 12,628     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Executive Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Frank Mathias 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP grant in respect of 2026 Nil 478,119 LTIP grant in respect of 2025 Nil 46,195 LTIP grant in respect of 2024 Nil 43,790 h) Aggregated information -       Aggregated volume LTIP awards granted over 478,119 shares in total -       Price   -       Aggregated volume -       -       Price   -       Aggregated volume -       Price Nil LTIP awards over 46,195 shares in total   Nil LTIP awards over 43,790 shares in total Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Executive Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Frank Mathias 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. g) Price(s) and volumes(s)   Award Price Volume DBP grant in respect of 2026 Nil 71,891 h) Aggregated information -       Aggregated volume DBP awards granted over 71,891 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Financial Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Lucinda Crabtree 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP grant in respect of 2026 Nil 156,884 LTIP grant in respect of 2025 Nil 26,526 LTIP grant in respect of 2024 Nil 12,876 h) Aggregated information -       Aggregated volume LTIP awards granted over 156,884 shares in total -       Price   -       Aggregated volume -       -       Price   -       Aggregated volume -       Price Nil LTIP awards over 26,526 shares in total   Nil   LTIP awards over 12,876 shares in total Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Financial Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Lucinda Crabtree 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. g) Price(s) and volumes(s)   Award Price Volume DBP grant in respect of 2026 Nil 47,179 h) Aggregated information -       Aggregated volume DBP awards granted over 47,179 shares in total -       Price Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Legal Officer and Group Company Secretary b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Natalie Walter 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP grant in respect of 2026 Nil 75,479 h) Aggregated information -       Aggregated volume LTIP awards granted over 75,479 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Legal Officer and Group Company Secretary b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Natalie Walter 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. g) Price(s) and volumes(s)   Award Price Volume DBP grant in respect of 2026 Nil 12,459 h) Aggregated information -       Aggregated volume DBP awards granted over 12,459 shares in total -       Price Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Business Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Sébastien Ribault 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP grant in respect of 2026 Nil 107,102 h) Aggregated information -       Aggregated volume LTIP awards granted over 107,102 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Business Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Sébastien Ribault 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. g) Price(s) and volumes(s)   Award Price Volume DBP grant in respect of 2026 Nil 14,908 h) Aggregated information -       Aggregated volume DBP awards granted over 14,908 shares in total -       Price Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief People Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Lisa Doman 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP grant in respect of 2026 Nil 69,992 h) Aggregated information -       Aggregated volume LTIP awards granted over 69,992 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief People Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Lisa Doman 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. g) Price(s) and volumes(s)   Award Price Volume DBP grant in respect of 2026 Nil 10,629 h) Aggregated information -       Aggregated volume DBP awards granted over 10,629 shares in total -       Price Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Innovation Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Kyriacos Mitrophanous 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP grant in respect of 2026 Nil 72,391 h) Aggregated information -       Aggregated volume LTIP awards granted over 72,391 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief Innovation Officer b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Kyriacos Mitrophanous 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of DBP award over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of the award. g) Price(s) and volumes(s)   Award Price Volume DBP grant in respect of 2026 Nil 10,841 h) Aggregated information -       Aggregated volume DBP awards granted over 10,841 shares in total -       Price Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Site Head, UK Operations b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Mark Caswell 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP grant in respect of 2026 Nil 49,431 h) Aggregated information -       Aggregated volume LTIP awards granted over 49,431 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Chief of Staff b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Sabine Sydow 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP RSU grant in respect of 2026 Nil 7,036 h) Aggregated information -       Aggregated volume LTIP RSU awards granted over 7,036 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Global Head of Quality b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Melanie Kearney 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP RSU grant in respect of 2026 Nil 12,711 h) Aggregated information -       Aggregated volume LTIP RSU awards granted over 12,711 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Site Head, Durham Operations b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person John Foy 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP RSU grant in respect of 2026 Nil 12,380 h) Aggregated information -       Aggregated volume LTIP RSU awards granted over 12,380 shares in total -       Price Nil     1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Site Head and General Manager of France Operations b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Stephanie Colloud 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP RSU grant in respect of 2026 Nil 10,357 h) Aggregated information -       Aggregated volume LTIP RSU awards granted over 10,357 shares in total -       Price Nil   1. Details of the Issuer or emission allowance market participant a) Full name of the entity Oxford Biomedica plc b) LEI code 213800S1GVQNXQ15K851 2. Reason for the notification a) Position/status Head of Human Resources (and acting Interim Site Head, Bedford) b) Initial notification / amendment Initial Notification 3. Details of the person discharging managerial responsibilities / person closely associated a) Is this a PDMR or PCA Submission Submission for PDMR b) Name of natural person Kathleen Miller 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Date of the transaction 2026-04-07 b) Description of instrument Share c) Identification code ISIN: GB00BDFBVT43 d) Place of the transaction Outside the trading venue e) Currency GBP - British Pound f) Nature of the transaction Grant of LTIP RSU awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of the awards. g) Price(s) and volumes(s)   Award Price Volume LTIP RSU grant in respect of 2026 Nil 12,628 h) Aggregated information -       Aggregated volume LTIP RSU awards granted over 12,628 shares in total -       Price Nil     -Ends-   Enquiries:        OXB: Natalie Walter, Chief Legal Officer and Group Company Secretary - T : +44 (0) 1865 783 000 / E: [email protected] ICR Healthcare: T: +44 (0)20 3709 5700 / E:  [email protected] Mary-Jane Elliott / Angela Gray / Davide Salvi     About OXB   OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.   One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector de velopment and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early - stage development to commercialisation. These capabilities are supported by robust q uality-assurance systems, analytical methods and depth of regulatory expertise.   OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetra V ecta™ system), a dual - plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.   OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France , Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.

View stock analysis, news, and events for Oxford Biomedica Plc